| 2.5 -0.05 (-1.96%) | 10-07 14:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.33  |
1-year : | 3.69 |
| Resists | First : | 2.85 |
Second : | 3.16 |
| Pivot price | 2.67 |
|||
| Supports | First : | 2.34 |
Second : | 1.95 |
| MAs | MA(5) : | 2.49 |
MA(20) : | 2.74 |
| MA(100) : | 2.81 |
MA(250) : | 2.95 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8 |
D(3) : | 3.7 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 5.25 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CYCN ] has closed above bottom band by 23.3%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.63 - 2.64 | 2.64 - 2.65 |
| Low: | 2.4 - 2.41 | 2.41 - 2.43 |
| Close: | 2.41 - 2.43 | 2.43 - 2.45 |
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Wed, 07 Aug 2024
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StockTitan
Wed, 07 Aug 2024
Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewswire
Mon, 31 Jul 2023
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewswire
Mon, 15 May 2023
Cyclerion Announces Reverse Stock Split - Yahoo Finance
Mon, 08 Aug 2022
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 21.8 (%) |
| Held by Institutions | 40 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 14 (K) |
| EPS | -4.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.6 % |
| Return on Equity (ttm) | -150.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|